2021-07-05

New test can distinguish SARS-CoV-2 from other coronaviruses with 100% accuracy

By yqqlm yqqlm

New test can distinguish SARS-CoV-2 from other coronaviruses with 100% accuracy

Researchers are now trying to observe this easy-to-use, Whether point-of-care equipment that does not rely on energy can be used to predict the severity of COVID-19 infection or a person’s immunity to a variant of the virus.

Researchers have also recently shown that the same “D4 test” platform can detect Ebola virus infection a day earlier than the gold standard polymerase chain reaction (PCR) test. They said these results indicate that The technology can be flexibly applied to other current or future diseases. The results will be published online in Science Advances on June 25, 2021.

Duke University Alan L. Kaganov Distinguished Professor and Head of the Department of Biomedical Engineering, Ashutosh Chilkoti, said: “The D4 test took six years to develop, but when the WHO declared the disease outbreak a pandemic When we were sick, we began to work hard to compress all these tasks into a few months so that we could explore how to use the test as a public health tool. Our test is designed to be both adaptable and a real medical point. This is clearly the most useful case for a portable, fast, and cost-effective diagnostic method.”

The technology relies on a polymer brush coating that acts as a non-stick coating to prevent removal. Anything other than the required biomarkers adheres to the test slide when wet. The high efficiency of this non-stick coating makes the D4 measurement extremely sensitive to the low level of its target. This method allows researchers to print different molecular traps on different areas of the slide to capture multiple biomarkers at once.

New test can distinguish SARS-CoV-2 from other coronaviruses with 100% accuracy(1)

The current iteration of the platform also has The tiny patterned tunnel uses the physical properties of the liquid to attract the sample into the channel without the need for any electricity. With just a drop of blood and a drop of biomolecular lubricant, the test can run autonomously in a few minutes and can be read by a detector about the size of a thick iPad.

Jason Liu, a doctoral student working in the Chilkoti laboratory, said: “The detector is powered by a battery, and the test does not require any power at all, so you can throw the whole thing in a backpack and use the least resources in the medical treatment. Click for a real test,” he designed and built the detector.

In the current study, the researchers tested the ability of the D4 detection method to detect and quantify the antibodies produced against the three parts of the COVID-19 virus-a subunit of spike glycoprotein, spike sugar A binding domain in the protein that grabs cells and a nucleocapsid protein that packages viral RNA. Two weeks later, the test was able to find antibodies in all 31 patients with severe cases of COVID-19 who were tested. It also reported that in 41 samples taken from healthy people before the pandemic began, and 18 samples from individuals infected with four other widespread coronaviruses, the false positive rate was zero.

As the pandemic subsides in the United States and hundreds of other COVID-19 antibody detection methods are developed, researchers believe that this particular test cannot be deployed in large numbers. But they said the proven accuracy and flexibility of the platform make it a prime candidate for developing other types of tests or for future outbreaks.

For example, the platform may be able to test whether people are immune to various strains of COVID-19 that are constantly emerging.

Jake Heggestad, a doctoral student working in the Chilkoti laboratory, said: “People have a lot of questions about whether they are protected by the new variant of COVID-19, and our tests can answer some of these questions,” he developed The tested chip. “We believe that our platform should be able to distinguish whether people have antibodies that can neutralize new and worrying variants, or that these antibodies will not protect against new variants.”